Towards a robust test to detect gene doping for anabolic enhancement in human athletes
© 2022 Commonwealth of Australia. Drug Testing and Analysis © 2022 John Wiley & Sons Ltd..
Success in gene therapy in treating human disease makes this technology attractive to enhance athletic performance, creating the need for gene doping detection. In 2021, World Anti-Doping Agency (WADA) approved the first gene doping test. Here, we describe a new method to detect doping with four additional genes, follistatin, growth hormone 1, growth hormone-releasing hormone and insulin-like growth factor 1, that may improve performance by increasing muscle size and strength. The method utilises four hydrolysis probe-based polymerase chain reaction (PCR) assays that target the transgenes based on the coding sequence of the four endogenous genes. The assays are specific, reproducible and capable to detect five copies of transgene in the presence of very similar endogenous gene in 25,000 times excess. To underpin reliable and comparable routine method performance by doping testing laboratories, a synthetic reference material for the method was designed and generated following the ISO Guide 35. The complete method was validated in blood samples using plasma as extraction matrix and QIAamp DNA blood midi DNA extraction kit. All blood samples from different donors (n = 8) simulated to be negative or positive (1500 transgene copies spiked per millilitre of blood) for the transgenes were reported correctly. The new method that targets four additional genes will extend the capabilities of laboratories involved in doping control to protect athletes' health, fairness and equality.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
---|---|
Enthalten in: |
Drug testing and analysis - 15(2023), 3 vom: 14. März, Seite 314-323 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Baoutina, Anna [VerfasserIn] |
---|
Links: |
---|
Themen: |
9007-49-2 |
---|
Anmerkungen: |
Date Completed 15.03.2023 Date Revised 15.03.2023 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1002/dta.3411 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM34958043X |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM34958043X | ||
003 | DE-627 | ||
005 | 20231226042953.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1002/dta.3411 |2 doi | |
028 | 5 | 2 | |a pubmed24n1165.xml |
035 | |a (DE-627)NLM34958043X | ||
035 | |a (NLM)36445200 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Baoutina, Anna |e verfasserin |4 aut | |
245 | 1 | 0 | |a Towards a robust test to detect gene doping for anabolic enhancement in human athletes |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 15.03.2023 | ||
500 | |a Date Revised 15.03.2023 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2022 Commonwealth of Australia. Drug Testing and Analysis © 2022 John Wiley & Sons Ltd. | ||
520 | |a Success in gene therapy in treating human disease makes this technology attractive to enhance athletic performance, creating the need for gene doping detection. In 2021, World Anti-Doping Agency (WADA) approved the first gene doping test. Here, we describe a new method to detect doping with four additional genes, follistatin, growth hormone 1, growth hormone-releasing hormone and insulin-like growth factor 1, that may improve performance by increasing muscle size and strength. The method utilises four hydrolysis probe-based polymerase chain reaction (PCR) assays that target the transgenes based on the coding sequence of the four endogenous genes. The assays are specific, reproducible and capable to detect five copies of transgene in the presence of very similar endogenous gene in 25,000 times excess. To underpin reliable and comparable routine method performance by doping testing laboratories, a synthetic reference material for the method was designed and generated following the ISO Guide 35. The complete method was validated in blood samples using plasma as extraction matrix and QIAamp DNA blood midi DNA extraction kit. All blood samples from different donors (n = 8) simulated to be negative or positive (1500 transgene copies spiked per millilitre of blood) for the transgenes were reported correctly. The new method that targets four additional genes will extend the capabilities of laboratories involved in doping control to protect athletes' health, fairness and equality | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a anabolic | |
650 | 4 | |a gene doping | |
650 | 4 | |a real-time PCR | |
650 | 4 | |a reference material | |
650 | 7 | |a DNA |2 NLM | |
650 | 7 | |a 9007-49-2 |2 NLM | |
700 | 1 | |a Bhat, Somanath |e verfasserin |4 aut | |
700 | 1 | |a Li, Desmond K |e verfasserin |4 aut | |
700 | 1 | |a Emslie, Kerry R |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Drug testing and analysis |d 2009 |g 15(2023), 3 vom: 14. März, Seite 314-323 |w (DE-627)NLM196999022 |x 1942-7611 |7 nnns |
773 | 1 | 8 | |g volume:15 |g year:2023 |g number:3 |g day:14 |g month:03 |g pages:314-323 |
856 | 4 | 0 | |u http://dx.doi.org/10.1002/dta.3411 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 15 |j 2023 |e 3 |b 14 |c 03 |h 314-323 |